A tetrapeptide derivative and its composition and use
By developing a polypeptide derivative, downregulating the expression of α-MSH and IL-6/TNF-α, the cytotoxicity and single effect of skin inflammation and melanination treatment in the prior art were solved, and whitening and anti-inflammatory Dual effect, used to improve post-inflammatory pigmentation.
Patent Information
- Application Number
- CN202180080629.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-11-04
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2041-11-04
AI Technical Summary
The prior art has problems of cytotoxicity, skin irritation or chemical instability in treating skin inflammation and inhibiting melanin hyperscaling, and a single compound can only anti-inflammatory or inhibit melanin production, making it difficult to solve both problems at the same time.
A polypeptide derivative was developed to improve post-inflammatory pigmentation by downregulating the expression of α-MSH and IL-6/TNF-α, which has both whitening and anti-inflammatory effects. The peptide derivative consists of specific amino acid sequences, including R1-Pro-Lys-Glu-Lys-R2, linked to niacin or kojic acid via covalent bonds, forming new structural compounds to enhance whitening and anti-inflammatory activity.
This peptide derivative significantly downregulates the expression of α-MSH, inhibits melanin production, has higher whitening activity than single niacin or kojic acid, and shows unexpected anti-inflammatory activity based on whitening effects, which can be used in cosmetics Or the medical field is used to anti-inflammatory and whitening and freckle removal in the skin, especially to improve post-inflammatory pigmentation.
Smart Images

Figure CN116528825B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a peptide derivative, a composition containing the peptide derivative and their use in improving or caring for skin or mucosa. Background Art
[0002] When the skin is exposed to the external environment, it is susceptible to various physical, chemical and pathogenic microbial stimuli, which can damage skin tissue cells and trigger inflammatory reactions. Inflammatory reactions not only increase skin permeability, leading to the release of collagenase and degradation of collagen and elastin, causing the skin to show sagging and aging symptoms; in addition, the inflammatory factors produced, such as interleukin IL-1α, IL-6 and tumor necrosis factor TNF-α, stimulate melanocyte migration, proliferation and differentiation, induce keratinocytes to produce precursor melanocyte-stimulating hormone (POMC) and melanocyte-stimulating hormone (α-MSH), enhance the activity of tyrosinase, increase melanin production in the skin, darken the skin surface or cause spots locally.
[0003] Post-inflammatory hyperpigmentation (PIH) is one of the common sequelae of skin inflammation. The specific pathogenesis of PIH is not yet fully understood, but as a secondary pigment abnormality, it is closely related to the degree of basement membrane damage, inflammation and melanocytes. Bastonini E found that melanocytes and their surrounding keratinocytes and fibroblasts play an important role in the occurrence of PIH. At the same time, the migration and proliferation of melanocytes, the synthesis and activation of tyrosinase, and the transfer of melanosomes to keratinocytes can also affect the occurrence of PIH. Some inflammatory regulatory factors such as inflammatory mediators, inflammatory factors and α-melanocyte stimulating hormone (α-MSH) also play a regulatory role in the above links to varying degrees.
[0004] The main method for treating PIH is to control the inflammatory response and inhibit the synthesis of melanin, and reduce the pigmentation that continues to occur with the micro-inflammatory state. At present, glucocorticoid drugs such as desonide and hydrocortisone are mainly used to control the inflammatory response. At the same time, other compounds are used to inhibit the synthesis or deposition of melanin. For example, arbutin, kojic acid and ascorbic acid can inhibit the synthesis of melanin by inhibiting the activity of tyrosinase, and nicotinic acid is converted into nicotinamide in the body to inhibit the transport of melanin particles from melanocytes to keratinocytes. However, these compounds usually have cytotoxicity, skin irritation or chemical instability, etc., and a single compound only has an effect of anti-inflammatory or inhibiting melanin production, and needs to be used in combination. Therefore, it is necessary to develop new compounds that can treat skin inflammatory reactions and can also be used to inhibit excessive melanin deposition to overcome the defects of the prior art. Summary of the invention
[0005] The present invention aims to provide a polypeptide derivative having both whitening and anti-inflammatory activity. These peptide derivatives and cosmetic compositions or pharmaceutical compositions containing these peptide derivatives exert whitening effects by down-regulating the expression of α-MSH; down-regulating the expression of IL-6 and TNF-α to exert anti-inflammatory activity, and can be used in the field of cosmetics or medicine for skin anti-inflammatory and whitening, especially for improving post-inflammatory pigmentation.
[0006] In view of this, the present invention provides a peptide derivative represented by general formula (I), or a stereoisomer thereof, or a mixture of stereoisomers, or a cosmetically acceptable salt thereof, or a pharmaceutically acceptable salt thereof,
[0007] R 1 -Pro-Lys-Glu-Lys-R 2 (I)
[0008] In formula (I),
[0009] R 1 is selected from: substituent (i), substituent (ii) or substituent (iii), wherein substituent (i) is
[0010]
[0011] Substituent (ii) is
[0012]
[0013] The substituent (iii) is
[0014]
[0015] R 2 Selected from:-NR 3 R 4 OR 3 , where each R 3 and R 4 are independently selected from: H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl;
[0016] The alkyl group refers to a saturated aliphatic straight or branched chain alkyl group having 1 to 24 carbon atoms (optionally having 1 to 16 carbon atoms; optionally having 1 to 14 carbon atoms; optionally having 1 to 12 carbon atoms; optionally having 1, 2, 3, 4, 5, or 6 carbon atoms); and may be selected from: methyl, ethyl, isopropyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, decyl, dodecyl, tetradecyl, hexadecyl, octadecyl, 2-ethylhexyl, 2-methylbutyl, or 5-methylhexyl;
[0017] The alkenyl group refers to a straight or branched alkenyl group having 2-24 carbon atoms (optionally having 2-16 carbon atoms; optionally having 2-14 carbon atoms; optionally having 2-12 carbon atoms; optionally having 2, 3, 4, 5, or 6 carbon atoms); the alkenyl group has one or more carbon-carbon double bonds, optionally having 1, 2 or 3 conjugated or non-conjugated carbon-carbon double bonds; the alkenyl group is bonded to the rest of the molecule through a single bond; and can be selected from: vinyl, oleyl, or linoleyl;
[0018] Optionally, the substituent in the "substituted alkyl" or "substituted alkenyl" is selected from C 1 -C 4 Alkyl; Hydroxyl; C 1 -C 4 Alkoxy; amino; C 1 -C 4 Aminoalkyl; C 1 -C 4 Carbonyloxy; C 1 -C 4 Oxycarbonyl; halogen (such as fluorine, chlorine, bromine, and iodine); cyano; nitro; azide; C 1 -C 4 Alkylsulfonyl; thiol; C 1 -C 4 Alkylthio; C 6 -C 30 Aryloxy such as phenoxy; -NR b (C=NR b )NR b R c , where R b and R c are independently selected from: H, C 1 -C 4 Alkyl, C 2 -C 4 Alkenyl, C 2 -C 4 Alkynyl, C 3 -C 10 Cycloalkyl, C 6 -C 18 Aryl, C 7 -C 17 an aralkyl group, a heterocyclic group having three to ten members, or a protecting group for an amino group.
[0019] Optionally, R 3 , R 4 are independently selected from: H, methyl, ethyl, hexyl, dodecyl or hexadecyl;
[0020] Optionally, R 3 is H and R 4Selected from: H, methyl, ethyl, hexyl, dodecyl or hexadecyl;
[0021] Optionally, R 2 Is -OH or -NH 2 .
[0022] The peptide derivative represented by formula (I), or its stereoisomer, or mixture of stereoisomers, or cosmetically acceptable salt thereof, or pharmaceutically acceptable salt thereof, is selected from the following peptide derivatives (1)-(6):
[0023] (1)
[0024] (2)
[0025] (3)
[0026] (4)
[0027] (5)
[0028] (6)
[0029] The peptide derivatives shown in formula (I) of the present invention may exist as stereoisomers or mixtures of stereoisomers; for example, the amino acids contained therein may have L-, D- configurations, or may be racemic independently of one another. Therefore, it is possible to obtain isomeric mixtures as well as racemic mixtures or diastereomeric mixtures, or pure diastereomers or enantiomers, depending on the number of asymmetric carbons and what isomers or isomeric mixtures are present. The preferred structure of the peptide derivatives shown in formula (I) of the present invention is a pure isomer, i.e., an enantiomer or a diastereomer.
[0030] For example, when -Lys- is described in the present invention, it should be understood that -Lys- is selected from -L-Lys-, -D-Lys-, or a mixture of the two, and is racemic or non-racemic. The preparation method described in this document enables a person skilled in the art to obtain each stereoisomer of the peptide derivative of the present invention by selecting an amino acid with the correct configuration.
[0031] The term "cosmetically acceptable salt or pharmaceutically acceptable salt" refers to a salt approved for use in animals, and more specifically in humans, including metal salts of the peptide derivatives shown in formula (I), the metals including, but not limited to, lithium, sodium, potassium, calcium, magnesium, manganese, copper, zinc or aluminum, etc.; including salts formed between the peptide derivatives shown in formula (I) and organic bases, the organic bases including, but not limited to, ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, arginine, lysine, histidine or piperazine, etc.; including salts formed between the peptide derivatives shown in formula (I) and inorganic acids or organic acids, the organic acids including, but not limited to, acetic acid, citric acid, lactic acid, malonic acid, maleic acid, tartaric acid, fumaric acid, benzoic acid, aspartic acid, glutamic acid, succinic acid, oleic acid, trifluoroacetic acid, oxalic acid, pamoate or gluconic acid, etc.; the inorganic acids including, but not limited to, hydrochloric acid, sulfuric acid, boric acid or carbonic acid.
[0032] Another aspect of the present invention provides a cosmetic or pharmaceutical composition, comprising an effective amount of the peptide derivative represented by the above formula (I), or its stereoisomer, or a mixture of stereoisomers, or its cosmetically acceptable salt, or its pharmaceutically acceptable salt, and at least one excipient and optionally a cosmetically or pharmaceutically acceptable adjuvant.
[0033] Optionally, the adjuvant is selected from: collagen synthesis stimulators, agents that regulate PGC-1α synthesis, agents that regulate the activity of PPARγ, agents that increase or decrease the triglyceride content of adipocytes, agents that stimulate or delay adipocyte differentiation, lipolytic agents or agents that stimulate fat decomposition, lipolytic agents, lipogenic agents, inhibitors of acetylcholine receptor aggregation, agents that inhibit muscle contraction, anticholinergic agents, elastase inhibitors, matrix metalloproteinase inhibitors, melanin synthesis stimulators or inhibitors, whitening agents or depigmenting agents, pigmentation promoting agents, self-tanning agents, anti-aging agents, NO-synthase inhibitors, 5α-reductase inhibitors, inhibitors of lysyl hydroxylase and / or prolyl hydroxylase, antioxidants, free radical scavengers and / or anti-atmospheric pollution agents, Reactive carbonyl scavengers, anti-glycation agents, antihistamines, antivirals, antiparasitic agents, emulsifiers, emollients, organic solvents, liquid propellants, skin conditioning agents, moisturizers, moisture retaining substances, alpha hydroxy acids, beta hydroxy acids, moisturizers, epidermal hydrolases, vitamins, amino acids, proteins, pigments or colorants, dyes, biopolymers, gelling polymers, thickeners, surfactants, softeners, adhesives, preservatives, anti-wrinkle agents, agents capable of reducing or treating under-eye bags, exfoliants, keratolytic agents, keratolytic agents, antimicrobial agents, antifungal agents, antifungal agents, bacteriostatic agents, bacteriostatic agents, agents that stimulate the synthesis of dermal or epidermal macromolecules and / or are capable of inhibiting or preventing their degradation, agents that stimulate elastin synthesis, stimulating agents that stimulate the synthesis of decorin, agents that stimulate the synthesis of laminin, agents that stimulate the synthesis of defensins, agents that stimulate the synthesis of chaperone proteins, agents that stimulate the synthesis of cAMP, heat shock proteins, agents that stimulate the synthesis of HSP70, agents that stimulate the synthesis of heat shock proteins, agents that stimulate the synthesis of hyaluronic acid, agents that stimulate the synthesis of fibronectin, agents that stimulate the synthesis of sirtuins, agents that stimulate the synthesis of lipids and stratum corneum components, ceramides, fatty acids, agents that inhibit collagen degradation, agents that inhibit elastin degradation, agents that inhibit serine proteases, agents that stimulate fibroblast proliferation, agents that stimulate keratinocyte proliferation, agents that stimulate adipocyte proliferation, agents that stimulate melanocyte proliferation, agents that stimulate keratinocyte differentiation, agents that inhibit acetylcholinesterase, skin skin relaxants, agents that stimulate glycosaminoglycan synthesis, anti-hyperkeratotic agents, comedolytic agents, anti-psoriatic agents, anti-dermatitis agents, anti-eczema agents, DNA repair agents, DNA protective agents, stabilizers, antipruritic agents, agents for treating and / or caring for sensitive skin, firming agents, firming agents, reconstructing agents, anti-stretch mark agents, adhesives, agents for regulating sebum production, antiperspirants, agents that stimulate healing, agents that assist healing, agents that stimulate re-epithelialization, agents that assist re-epithelialization, cytokine growth factors, sedatives, anti-inflammatory agents, anesthetics, agents that act on capillary circulation and / or microcirculation, agents that stimulate angiogenesis, agents that inhibit vascular permeability, venous tension agents, agents that act on cell metabolism, agents for improving dermal-epidermal junction, agents that induce hair growth,Hair growth inhibiting or retarding agents, fragrances, chelating agents, plant extracts, essential oils, marine extracts, agents obtained from biological fermentation processes, inorganic salts, cell extracts, sunscreens, and organic or inorganic photoprotective agents effective against A and / or B ultraviolet rays, or mixtures thereof.
[0034] Optionally, the formulation of the cosmetic or pharmaceutical composition is selected from the group consisting of: cream, oil, milk, balm, foam, lotion, gel, liniment, serum, soap, shampoo, conditioner, serum, ointment, mousse, pomade, powder, stick, pen, spray, aerosol, capsule, tablet, granule, chewing gum, solution, suspension, emulsion, syrup, elixir, polysaccharide film, jelly or gelatin;
[0035] Optionally, the capsule includes: a soft capsule, a hard capsule, and may be a gelatin capsule;
[0036] Optionally, the tablet comprises: a sugar-coated tablet.
[0037] The peptide derivatives of the present invention have variable solubility in water, depending on the nature of their sequence or any possible modification in the N-terminus and / or C-terminus. The peptide derivatives of the present invention can therefore be incorporated into the composition via an aqueous solution, and those that are insoluble in water can be dissolved in conventional cosmetically or pharmaceutically acceptable solvents, such as, but not limited to, ethanol, propanol, isopropanol, propylene glycol, glycerol, butylene glycol or polyethylene glycol or any combination thereof.
[0038] The cosmetically or pharmaceutically effective amount of the peptide derivatives of the invention to be administered and their dosage will depend on many factors, including the age, condition of the patient, severity of the disorder or disease, route and frequency of administration and the specific nature of the peptide derivative to be used.
[0039] "Cosmetically or pharmaceutically effective amount" means an amount of one or more peptide derivatives of the present invention that is non-toxic but sufficient to provide the desired effect. The peptide derivatives of the present invention are used in cosmetic or pharmaceutical compositions of the present invention at cosmetically or pharmaceutically effective concentrations to obtain the desired effect; in a preferred form, between 0.00000001% (by weight) and 20% (by weight), preferably between 0.000001% (by weight) and 15% (by weight), more preferably between 0.0001% (by weight) and 10% (by weight), and even more preferably between 0.0001% (by weight) and 5% (by weight), relative to the total weight of the composition.
[0040] Another aspect of the present invention provides a cosmetically or pharmaceutically acceptable delivery system or sustained-release system to achieve better penetration of the active ingredient and / or improve its pharmacokinetic and pharmacodynamic properties, which comprises an effective amount of the peptide derivative represented by the above formula (I), or its stereoisomer, or a mixture of stereoisomers, or its cosmetically acceptable salt, or its pharmaceutically acceptable salt, or the above cosmetic or pharmaceutical composition.
[0041] The term "delivery system" refers to a diluent, adjuvant, excipient or carrier used together with the peptide derivatives of the present invention, which is selected from: water, oil or surfactant, including those of petroleum origin, animal origin, plant origin or synthetic origin, such as and not limited to peanut oil, soybean oil, mineral oil, sesame oil, castor oil, polysorbate, sorbitan ester, ether sulfate, sulfate, betaine, glucosides, maltoside, fatty alcohol, nonoxynol ether, poloxamer, polyoxyethylene, polyethylene glycol, dextrose, glycerol, digitonin and the like. Those of ordinary skill in the art are known to those of ordinary skill in the art that can administer the diluents that can be used in the different delivery systems of the peptide derivatives of the present invention.
[0042] The term "sustained release" is used in its conventional sense to refer to a delivery system that provides for gradual release of a compound over a period of time, and preferably, but not necessarily, with a relatively constant level of compound released over the entire period of time.
[0043] Examples of delivery systems or sustained release systems are liposomes, oleosomes, nonionic surfactant liposome vesicles, ethosomes, millicapsules, microcapsules, nanocapsules, nanostructured lipid carriers, sponges, cyclodextrins, lipid vesicles, micelles, millispheres, microspheres, nanospheres, lipid spheres, microemulsions, nanoemulsions, milliparticles, microparticles or nanoparticles. Preferred delivery systems or sustained release systems are liposomes and microemulsions, more preferably water-in-oil microemulsions with an internal structure of reverse micelles.
[0044] Sustained-release system can be prepared by methods known in the prior art, and can be given, for example, in the following manner: by topical or transdermal administration, including adhesive patch, non-adhesive patch, closure patch, and microelectronic patch; or by systemic administration, for example and not limited to, oral or parenteral route, including nasal, rectal, subcutaneous implantation or injection, or directly implanted or injected into a specific body part, and preferably these peptide derivatives of the present invention of a relatively constant amount should be released. The amount of the peptide derivatives included in the sustained-release system will depend on the release kinetics and duration of the position to which the composition will be given, the peptide derivatives of the present invention, and the condition to be treated and / or the property of care, illness and / or disease.
[0045] Another aspect of the present invention provides a peptide derivative represented by the above formula (I), or a stereoisomer thereof, or a mixture of stereoisomers, or a cosmetically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or the above cosmetic or pharmaceutical composition, or the above cosmetically or pharmaceutically acceptable delivery system or sustained-release system in the preparation of a cosmetic composition or pharmaceutical composition for treating or caring for the skin or mucous membranes.
[0046] Another aspect of the present invention provides a peptide derivative represented by the above formula (I), or a stereoisomer thereof, or a mixture of stereoisomers, or a cosmetically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or the above cosmetic or pharmaceutical composition, or the above cosmetically or pharmaceutically acceptable delivery system or sustained-release system in the preparation of a cosmetic composition or pharmaceutical composition for whitening.
[0047] Another aspect of the present invention provides a peptide derivative represented by the above formula (I), or a stereoisomer thereof, or a mixture of stereoisomers, or a cosmetically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or the above cosmetic or pharmaceutical composition, or the above cosmetically or pharmaceutically acceptable delivery system or sustained-release system in the preparation of an anti-inflammatory cosmetic composition or pharmaceutical composition.
[0048] Another aspect of the present invention provides a peptide derivative represented by the above formula (I), or a stereoisomer thereof, or a mixture of stereoisomers, or a cosmetically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or the above cosmetic or pharmaceutical composition, or the above cosmetically or pharmaceutically acceptable delivery system or sustained-release system in the preparation of a cosmetic composition or pharmaceutical composition for improving post-inflammatory pigmentation.
[0049] In order to facilitate the understanding of the present invention, the meanings of some terms and expressions used in the present invention are explained as follows:
[0050] In the present invention, the term "skin" is understood to mean the multiple layers that make it up, from the uppermost layer or stratum corneum to the lowermost layer or subcutaneous tissue, both ends are included. These layers are composed of different types of cells, such as keratinocytes, fibroblasts, melanocytes, and / or adipocytes, etc. In the present invention, the term "skin" includes the scalp.
[0051] The term "treatment" refers to administering a peptide derivative of the present invention to alleviate or eliminate a disease or condition, or to reduce or eliminate one or more symptoms associated with the disease or condition. The term "treatment" also encompasses the ability to alleviate or eliminate the physiological consequences of the disease or condition.
[0052] The term "care" includes the prevention of diseases and / or conditions.
[0053] In the present specification, the abbreviations used for amino acids follow the rules specified by the IUPAC-IUB Commission of Biochemical Nomenclature in the European Journal of Biochemistry (Eur. J. Biochem. 1984, 138: 9-37).
[0054] Thus, for example, Lys represents NH 2 -CH(CH 2 CH 2 CH 2 CH 2 NH 2 )-COOH, Lys- represents NH 2 -CH(CH 2 CH 2 CH 2 CH 2 NH 2 )-CO-, -Lys represents -NH-CH(CH 2 CH 2 CH 2 CH 2 NH 2 )-COOH, and -Lys- represents -NH-CH(CH 2 CH 2 CH 2 CH 2 NH 2 )-CO-. Thus, the hyphen representing a peptide bond eliminates the OH from the 1-carboxyl group of an amino acid (represented here in conventional non-ionized form) when located on the right side of the symbol, and eliminates the H from the 2-amino group of an amino acid when located on the left side of the symbol; both modifications can be applied to the same symbol (see Table 1).
[0055] Table 1 Structures of amino acid residues and their one-letter and three-letter abbreviations
[0056]
[0057]
[0058] The beneficial effects achieved by the present invention compared with the prior art include:
[0059] 1. The peptide derivatives described in the present invention are obtained through artificial design and are easy to synthesize.
[0060] 2. The new structure compound obtained by covalently connecting the N-terminus of H-Pro-Lys-Glu-Lys-OH to nicotinic acid, tranexamic acid and kojic acid can downregulate the expression of α-MSH, inhibit the formation of melanin, and exert a whitening effect. It has higher whitening activity than single nicotinic acid, tranexamic acid or kojic acid, and single polypeptide H-Pro-Lys-Glu-Lys-OH.
[0061] 3. The new structure compound obtained by covalently connecting the N-terminus of H-Pro-Lys-Glu-Lys-OH to niacin, tranexamic acid, and kojic acid can downregulate the expression of IL-6 and TNF-α, and on the basis of whitening effect, it shows unexpected anti-inflammatory activity.
[0062] 4. The peptide derivatives of the present invention have both whitening and anti-inflammatory activities, and can be used in the cosmetics or pharmaceutical fields for skin anti-inflammatory and whitening freckle removal, especially for improving post-inflammatory pigmentation. BRIEF DESCRIPTION OF THE DRAWINGS
[0063] Figure 1 This figure shows the effect of the peptide derivatives of the present invention on the activity of HaCaT cells (n=4).
[0064] Figure 2 This is a graph showing the effect of 100 ppm of the peptide derivative of the present invention on α-MSH expression. * indicates that the difference between the drug group and the control group is statistically significant, p<0.05 (n=4). ** indicates that the difference between the drug group and the control group is significant, p<0.01 (n=4). *** indicates that the difference between the drug group and the control group is extremely significant, p<0.001 (n=4).
[0065] Figure 3 This is a graph showing the effect of 50 ppm of the peptide derivative of the present invention on IL-6 expression. ## indicates that the UV group is significantly different from the control group, p<0.01 (n=4). ** indicates that the drug group is significantly different from the UV group, p<0.01 (n=4). *** indicates that the drug group is extremely significantly different from the UV group, p<0.001 (n=4).
[0066] Figure 4 This is a graph showing the effect of 50 ppm of the peptide derivative of the present invention on TNF-α expression. ## indicates that the UV group is significantly different from the control group, p<0.01 (n=4). * indicates that the drug group is statistically different from the UV group, p<0.05 (n=4). ** indicates that the drug group is significantly different from the UV group, p<0.01 (n=4). *** indicates that the drug group is extremely significantly different from the UV group, p<0.001 (n=4). DETAILED DESCRIPTION
[0067] In order to better understand the present invention, the invention is described in detail below in conjunction with embodiments and drawings. However, it should be understood that these embodiments and drawings are only used for illustrative purposes and are not intended to limit the scope of the present invention.
[0068] abbreviation
[0069] The abbreviations used for amino acids follow the rules specified by the Biochemical Nomenclature Commission of the IUPAC-IUB in Eur J. Biochem. (1984) 138:9-37 and J. Chem (1989) 264:633-673.
[0070] 2-Cl-Trt resin: 2-chlorotrityl resin, a starting resin for peptide synthesis (cross-linking degree 1%, substitution degree 1.24mmol / g); Trt: trityl; DMF: N,N-dimethylformamide; DCM: dichloromethane; DIPEA: diisopropylethylamine; DIC: diisopropylcarbodiimide; piperidine: piperidine; HOBt: 1-hydroxybenzotriazole; TFA: trifluoroacetic acid; TIS: triisopropylsilane; Pro: proline; Lys: lysine; Glu: glutamic acid; Fmoc: 9-fluorenylmethoxycarbonyl; Boc: tert-butoxycarbonyl; OtBu: tert-butoxy; CDI: N,N'-carbonyldiimidazole; Py: pyridine;
[0071] NA:
[0072] "NA-":
[0073] TXC:
[0074] "TXC-":
[0075] KA:
[0076] "KA-CO-":
[0077] According to the amino acid structure at the carboxyl end of the polypeptide sequence, the corresponding resin is selected as the carrier for solid phase synthesis.
[0078] The resin is added to swell, the resin is washed with a solvent, activated amino acids are added, and the amino acids are connected in sequence from the carboxyl end to the amino end in a coupling solvent according to the peptide sequence under the action of the coupling system, and the resin is washed to obtain a peptide-based resin.
[0079] Specifically, Fmoc-Lys(Boc)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Lys(Boc)-OH, and Fmoc-Pro-OH were sequentially added for reaction until all amino acids were connected. The column was washed with dichloromethane and then dried to obtain Fmoc-Pro-Lys(Boc)-Glu(OtBu)-Lys(Boc)-resin, which was divided into three batches.
[0080] Take one of the above-mentioned peptide-based resins, couple NA to obtain NA-Pro-Lys(Boc)-Glu(OtBu)-Lys(Boc)-resin, and then cleave, concentrate, precipitate, centrifuge, and vacuum dry to obtain a crude peptide; purify by reversed-phase high-performance liquid chromatography, and freeze-dry to obtain NA-Pro-Lys-Glu-Lys-OH or NA-Pro-Lys-Glu-Lys-NH 2 .
[0081] Take one batch of the above peptide-based resin, couple it with Fmoc-TXC-OH to obtain Fmoc-TXC-Pro-Lys(Boc)-Glu(OtBu)-Lys(Boc)-resin, and then cleave, concentrate, precipitate, centrifuge and vacuum dry to obtain crude peptide; purify by reverse phase high performance liquid chromatography and freeze-dry to obtain TXC-Pro-Lys-Glu-Lys-OH or TXC-Pro-Lys-Glu-Lys-NH 2 .
[0082] KA cannot directly form an amide bond with the N-terminus of the polypeptide. Therefore, in the presence of Py and DMF, KA reacts with CDI to form a KA-CO-imidazole intermediate, which is then covalently bonded to the N-terminus of the polypeptide.
[0083]
[0084] Take one of the above-mentioned peptide-based resins, couple it with KA-CO-imidazole intermediate to obtain KA-CO-Pro-Lys(Boc)-Glu(OtBu)-Lys(Boc)-resin, and then cleave, concentrate, precipitate, centrifuge and vacuum dry to obtain crude peptide; purify by reverse phase high performance liquid chromatography and freeze-dry to obtain KA-CO-Pro-Lys-Glu-Lys-OH or KA-CO-Pro-Lys-Glu-Lys-NH 2 .
[0085] Example 1 Preparation of Fmoc-Pro-Lys(Boc)-Glu(OtBu)-Lys(Boc)-2-Cl-Trt Resin
[0086] 1.1 Swelling of resin
[0087] Spray the column wall with 200ml DMF and drain for 3min. Spray the column wall with 200ml DMF again and drain for 5min. Add 20g of 2-Cl-Trt resin with a substitution degree of 1.42mmol / g into the solid phase column, add 200ml DMF to completely immerse the resin, then introduce nitrogen, start stirring at 100r / min, stir for 5min, and then drain the solvent for 5min. Add another 200ml DMF, completely immerse the resin, then introduce nitrogen, start stirring at 100r / min, stir for 30min, and drain the solvent. Continue to add 200ml DMF, completely immerse the resin, then introduce nitrogen, start stirring at 100r / min, and drain the solvent for 5min until swelling is complete.
[0088] 1.2 Removal of Fmoc
[0089] Add 200 ml of 20% piperidine / DMF, introduce nitrogen, stir for 5 minutes, and drain for 3 minutes. Add another 200 ml of 20% piperidine / DMF, introduce nitrogen, stir for 8 minutes, and drain for 3 minutes. Then add 200 ml of DMF, introduce nitrogen, stir for 1-2 minutes, and drain for 3 minutes. Repeat the resin washing 7-8 times.
[0090] 1.3 Feeding reaction
[0091] 17.4 g of Fmoc-Lys(Boc)-OH was dissolved in 100 ml of DMF containing 4.3 ml of DIPEA (1.5 eq), added to a solid phase reactor, coupled with 2-Cl-Trt resin, reacted for 14 h, then filtered and washed, treated with methanol for 1 h to block the remaining chloride groups.
[0092] The substitution degree was detected to be 0.55 mmol / g, and the synthesis scale was determined to be 16.7 mmol. On this basis, the amounts of the remaining amino acid raw materials and reagents were calculated as shown in Table 2 below.
[0093] Table 2 Amounts of amino acid raw materials and reagents
[0094] Serial number Amino acid raw material name Dosage(g) Multiples of synthetic scale HOBt(g) DIC(g) 1 Fmoc-Glu(OtBu)-OH 17.8 2.5 6.8 7 2 Fmoc-Lys(Boc)-OH 19.5 2.5 6.8 7 3 Fmoc-Pro-OH 14.1 2.5 6.8 7
[0095] The N-terminal Fmoc group was deprotected and 17.8 g of activated Fmoc-Glu(OtBu)-OH was coupled to the peptidyl resin using DMF as solvent in the presence of 6.8 g HOBt and 7 g DIC for 2.5 h. The resins were then washed and the deprotection of the Fmoc group was repeated to couple the next amino acid.
[0096] In each coupling, 19.5 g of Fmoc-Lys(Boc)-OH; 14.1 g of Fmoc-Pro-OH were coupled sequentially in the presence of 6.8 g of HOBt and 7 g of DIC using DMF as solvent.
[0097] 1.4 After the reaction is completed, wash the resin
[0098] After the above synthesis, the resin was washed with DMF, each time with an amount of 100 ml. After the resin and the solvent were evenly mixed, they were stirred for 2 minutes and the solvent was drained. The resin was washed with DMF several times until the solvent filtered out was clear and transparent. After shrinkage and drying, Fmoc-Pro-Lys(Boc)-Glu(OtBu)-Lys(Boc)-2-Cl-Trt resin was obtained.
[0099] Example 2 Preparation of NA-Pro-Lys-Glu-Lys-OH
[0100] 2.1 Preparation of NA-Pro-Lys(Boc)-Glu(OtBu)-Lys(Boc)-2-Cl-Trt resin
[0101] Weigh 10 g of Fmoc-Pro-Lys(Boc)-Glu(OtBu)-Lys(Boc)-2-Cl-Trt resin and add it to a 100 ml solid phase column. After swelling with DMF, wash it 3 times with DMF, remove Fmoc with 20% piperidine / DMF solution, wash it, and K test (5% ethylenediamine ethanol solution). The color is dark blue.
[0102] In the presence of 2.65g DIC and 2.27g HOBt, 1.71g NA was reacted with the above-mentioned Fmoc-protected peptidyl resin for 2h. K test showed that the resin was colorless and transparent. It was washed with DMF 3 times, 30ml each time, and washed with DCM 2 times, 30ml each time. It was shrunk with 30ml methanol and air-dried to obtain NA-Pro-Lys(Boc)-Glu(OtBu)-Lys(Boc)-2-Cl-Trt resin.
[0103] 2.2 Preparation of NA-Pro-Lys-Glu-Lys-OH
[0104] 2.2.1 Lysis buffer preparation
[0105] Measure 24.75 ml of TFA, 1.5 ml of TIS, and 1.5 ml of water, mix and stir, and place in a -18°C refrigerator for later use.
[0106] 2.2.2 Lysis
[0107] Weigh 10g of NA-Pro-Lys(Boc)-Glu(OtBu)-Lys(Boc)-2-Cl-Trt resin, add it to a 100ml round-bottom flask, add 30ml of the frozen lysate, and stir to react for 2h. Filter and concentrate to 10ml, then add isopropyl ether to precipitate a white solid, wash it with isopropyl ether 6 times until the pH value is 3-4, and dry it in vacuum. 6g of crude peptide (purity 85%) is obtained.
[0108] 2.2.3 Purification
[0109] Weigh 6 g of crude peptide and dissolve it in 85 ml of pure water to obtain a light yellow liquid. Filter through a 0.22 μm microporous filter membrane to obtain a light yellow clear transparent solution. Purify it through reverse phase HPLC. The purification gradient is as follows:
[0110] Time (min) Flow rate (ml / min) A% (0.1% acetic acid + acetonitrile) B% (0.1% acetic acid + pure water) 0 15 2 98 20 15 10 90 30 15 20 80 35 15 50 50 40 15 50 50
[0111] The filtered sample was injected for purification, and the fractions were collected, concentrated and lyophilized to obtain a peptide derivative (1) NA-Pro-Lys-Glu-Lys-OH with a purity of 97.97%.
[0112] Example 3 Preparation of TXC-Pro-Lys-Glu-Lys-OH
[0113] 3.1 Preparation of TXC-Pro-Lys(Boc)-Glu(OtBu)-Lys(Boc)-2-Cl-Trt resin
[0114] Weigh 10 g of Fmoc-Pro-Lys(Boc)-Glu(OtBu)-Lys(Boc)-2-Cl-Trt resin and add it to a 100 ml solid phase column. After swelling with DMF, wash it 3 times with DMF, remove Fmoc with 20% piperidine / DMF solution, wash it, and K test (5% ethylenediamine ethanol solution). The color is dark blue.
[0115] In the presence of 2.65g DIC and 2.27g HOBt, 5.31g Fmoc-TXC-OH was reacted with the above-mentioned Fmoc-protected peptidyl resin for 2h, and the K test showed that the resin was colorless and transparent. Fmoc was removed with 20% piperidine / DMF solution, washed with DMF 3 times, 30ml each time, and washed with DCM 2 times, 30ml each time. Shrink with 30ml methanol and air-dried to obtain TXC-Pro-Lys(Boc)-Glu(OtBu)-Lys(Boc)-2-Cl-Trt resin.
[0116] 3.2 Preparation of TXC-Pro-Lys-Glu-Lys-OH
[0117] 3.2.1 Lysis buffer preparation
[0118] Measure 24.75 ml of TFA, 1.5 ml of TIS, and 1.5 ml of water, mix and stir, and place in a -18°C refrigerator for later use.
[0119] 3.2.2 Lysis
[0120] Weigh 10g of TXC-Pro-Lys(Boc)-Glu(OtBu)-Lys(Boc)-2-Cl-Trt resin, add it to a 100ml round-bottom flask, add 30ml of the frozen lysate, and stir to react for 2h. Filter and concentrate to 10ml, then add isopropyl ether to precipitate a white solid, wash it with isopropyl ether 6 times until the pH value is 3-4, and dry it in vacuum. 5.7g of crude peptide (purity 87%) is obtained.
[0121] 3.2.3 Purification
[0122] Weigh 5.7 g of crude peptide and dissolve it in 85 ml of pure water to obtain a light yellow liquid. Filter through a 0.22 μm microporous filter membrane to obtain a light yellow clear transparent solution. Purify it through reverse phase HPLC. The purification gradient is as follows:
[0123] Time (min) Flow rate (ml / min) A% (0.1% acetic acid + acetonitrile) B% (0.1% acetic acid + pure water) 0 15 15 85 15 15 25 75 16 15 60 40 21 15 60 40 22 15 15 85
[0124] The filtered sample was injected for purification, and the fractions were collected, concentrated and lyophilized to obtain a peptide derivative (3) TXC-Pro-Lys-Glu-Lys-OH with a purity of 96.50%.
[0125] Example 4 Preparation of KA-CO-Pro-Lys-Glu-Lys-OH
[0126] 4.1 Synthesis of KA-CO-imidazole intermediate
[0127]
[0128] In a 250ml three-necked flask, add KA (50g, 35.2mmol), dissolve in 150ml of DMF, add Py (8g, 100mmol), cool to 0℃, add CDI (6.6g, 40mmol) and react for 4h. The reaction is complete according to TLC analysis (developing solvent: MeOH:DCM=1:20, Rf value 0.67).
[0129] The reaction solution was poured into ice water, and a large amount of white solid precipitated. After filtration, it was washed with ice water until there was no odor, and vacuum dried to obtain 74 g of product with a yield of 89.05%.
[0130] 4.2 Preparation of KA-CO-Pro-Lys(Boc)-Glu(OtBu)-Lys(Boc)-2-Cl-Trt resin
[0131] Weigh 10 g of Fmoc-Pro-Lys(Boc)-Glu(OtBu)-Lys(Boc)-2-Cl-Trt resin and add it to a 100 ml solid phase column. After swelling with DMF, wash it 3 times with DMF, remove Fmoc with 20% piperidine / DMF solution, wash it, and K test (5% ethylenediamine ethanol solution). The color is dark blue.
[0132] In the presence of 3.62g DIPEA, 3.31g of KA-CO-imidazole intermediate was reacted with the above-mentioned Fmoc-protected peptidyl resin for 2h. K detection showed that the resin was colorless and transparent. It was washed with DMF 3 times, 30ml each time, and washed with DCM 2 times, 30ml each time. It was shrunk with 30ml methanol and air-dried to obtain KA-CO-Pro-Lys(Boc)-Glu(OtBu)-Lys(Boc)-2-Cl-Trt resin.
[0133] Preparation of KA-CO-Pro-Lys-Glu-Lys-OH
[0134] 4.3.1 Lysis buffer preparation
[0135] Measure 24.75 ml of TFA, 1.5 ml of thioanisole, 1.5 ml of phenol, 1.5 ml of water, and 0.75 ml of EDT, mix and stir, and place in a -18°C refrigerator for later use.
[0136] 4.3.2 Lysis
[0137] Weigh 10g of KA-CO-Pro-Lys(Boc)-Glu(OtBu)-Lys(Boc)-2-Cl-Trt resin, add it to a 100ml round-bottom flask, add 30ml of the frozen lysate, and stir to react for 2h. Filter and concentrate to 10ml, then add isopropyl ether to precipitate a white solid, wash it with isopropyl ether 6 times until the pH value is 3-4, and dry it in vacuum. 5.7g of crude peptide (purity 83.5%) is obtained.
[0138] 4.3.3 Purification
[0139] Weigh 5.7 g of crude peptide and dissolve it in 65 ml of pure water to obtain a light yellow liquid. Filter through a 0.22 μm microporous filter membrane to obtain a light yellow clear transparent solution. Purify it through reverse phase HPLC. The purification gradient is as follows:
[0140] Time (min) Flow rate (ml / min) A% (0.1% acetic acid + acetonitrile) B% (0.1% acetic acid + pure water) 0 15 0 100 30 15 27 75 31 15 50 50 35 15 50 50
[0141] The filtered sample was injected for purification, and the fractions were collected, concentrated and lyophilized to obtain the peptide derivative (5) KA-CO-Pro-Lys-Glu-Lys-OH with a purity of 97.34%.
[0142] Example 5
[0143] Other compounds of formula (I) of the present invention can be prepared by similar methods.
[0144] The molecular weights of the obtained peptide derivatives were determined by ESI-MS, and the test results of some compounds are shown in Table 3 below.
[0145] Table 3 Molecular weight determination by mass spectrometry
[0146]
[0147]
[0148] Example 6 Cell activity experiment
[0149] 6.1 Reagents and Materials
[0150] Phosphate buffered saline (PBS) (Gibco), MTT (MTT) (Sigma), dimethyl sulfoxide (DMSO) (Sigma), DMEM (DMEM) (Gibco), and fetal bovine serum (Gibco).
[0151] 6.2 Instruments
[0152] ELISA reader (MD, USA), CO 2 Incubator (Shanghai Yiheng), clean bench (Suzhou Purification).
[0153] 6.3 Cell lines
[0154] Human keratinocytes (HaCaT) were purchased from the Kunming Cell Bank of Type Culture Collection of the Chinese Academy of Sciences.
[0155] 6.4 Samples to be tested
[0156] Drug group:
[0157] peptide H-Pro-Lys-Glu-Lys-OH (hereinafter referred to as reference peptide), tested at concentrations of 1 ppm, 10 ppm, 100 ppm, and 200 ppm;
[0158] Peptide (1), tested at concentrations of 1 ppm, 10 ppm, 100 ppm, and 200 ppm;
[0159] Peptide (3), tested at concentrations of 1 ppm, 10 ppm, 100 ppm, and 200 ppm;
[0160] Peptide (5), tested at concentrations of 1 ppm, 10 ppm, 100 ppm, and 200 ppm.
[0161] Control group:
[0162] PBS blank control.
[0163] 6.5 Experimental Purpose
[0164] The purpose of this experiment is to determine the effect of the peptide derivatives of the present invention on cell activity by evaluating the cell activity 72 hours after administration using HaCaT cells as experimental subjects.
[0165] 6.6 Experimental methods
[0166] Cryopreserved HaCaT cells were cultured and passaged at a ratio of 1:2 until about the fifth generation, and cells with better growth were selected as experimental subjects.
[0167] 2000 cells / well were inoculated in a 96-well plate. After the cells adhered to the wall, samples of the treatment group and the control group were added according to the doubling dilution method, and the culture medium was supplemented to 200 μL. The plate was placed at 37°C and 5% CO. 2 Incubate in an incubator for 72 h.
[0168] Then, 22 μL of 5 mg / ml MTT was added to each well and the cells were incubated at 37°C and 5% CO. 2 Incubate in the incubator for 4 hours. Discard the original solution and add 150 μL / well of DMSO. After 5 minutes, use a microplate reader to read the reference OD values at 490 nm and 630 nm.
[0169] 6.7 Results
[0170] The MTT assay is a method for detecting cell survival and growth. The measured OD value is proportional to the cell activity.
[0171] Figure 1 The results of HaCaT cell activity detection show that compared with the control group, peptide (1), peptide (3) and peptide (5) have no significant effect on the activity of HaCaT cells, indicating that the peptide derivatives of the present invention have no toxicity to HaCaT cells within the dosage range of 0-200 ppm.
[0172] Example 7 Cell experiment to inhibit α-MSH production
[0173] 7.1 Reagents and Materials
[0174] Fetal bovine serum, DMEM culture medium, penicillin, streptomycin, α-MSH ELISA kit.
[0175] 7.2 Instruments
[0176] ELISA reader, CO 2 Incubator, constant temperature shaker.
[0177] 7.3 Cell lines
[0178] Human keratinocytes (HaCaT) were purchased from the Kunming Cell Bank of Type Culture Collection of the Chinese Academy of Sciences.
[0179] 7.4 Samples to be tested
[0180] Drug group:
[0181] 100 ppm reference peptide, 100 ppm peptide (1), 100 ppm peptide (3), 100 ppm peptide (5), 100 ppm NA, 100 ppm TXC, 100 ppm KA.
[0182] Control group:
[0183] PBS blank control.
[0184] 7.5 Experimental methods
[0185] Cryopreserved HaCaT cells were cultured and passaged at a ratio of 1:2 until about the fifth generation, and cells with better growth were selected as experimental subjects.
[0186] When the cells were grown to about 80%, the samples were added in groups. The control group was added with PBS solution and supplemented with culture medium to 1000 μL. The drug group was added with double dilution of active substance and culture medium to 1000 μL. The cells were kept at 37°C and 5% CO. 2 Incubate in an incubator for 48 hours. After the incubation, centrifuge at 3000 rpm for 10 minutes, collect the cell supernatant to obtain the sample solution, and operate according to the instructions of the α-MSH kit.
[0187] 7.6 Results
[0188] α-MSH can promote the formation of melanin by activating tyrosinase. Therefore, downregulating the expression of α-MSH can reduce melanin production and play a whitening role.
[0189] The results of the effect of 100 ppm of the peptide derivatives of the present invention on the expression of α-MSH are shown in Figure 2 The results showed that compared with the control group, the reference peptide, NA, TXC, and KA could inhibit the expression of α-MSH to a certain extent, but except for TXC, the inhibitory effects of 100 ppm of the reference peptide, NA, and KA on α-MSH were not statistically different from those of the control group.
[0190] In contrast, the new structural compounds peptide (1), peptide (3), and peptide (5) obtained by covalently linking the N-terminus of the reference peptide to NA, TXC, and KA respectively can significantly downregulate the expression of α-MSH, and have higher activity than NA, TXC or KA alone, and the reference peptide alone, producing unexpected technical effects, among which peptide (1) has the strongest effect in inhibiting α-MSH. This shows that the peptide derivatives of the present invention have a better whitening effect than NA, TXC or KA alone, and the reference peptide alone, by significantly downregulating the expression of α-MSH and thereby inhibiting melanin production.
[0191] Example 8 Anti-inflammatory Cell Experiment
[0192] 8.1 Reagents and Materials
[0193] Fetal bovine serum, DMEM culture medium, penicillin, streptomycin, IL-6 ELISA kit, TNF-α ELISA kit.
[0194] 8.2 Instruments
[0195] ELISA reader, constant temperature CO 2 Incubator, constant temperature shaker.
[0196] 8.3 Cell lines
[0197] Human keratinocytes (HaCaT) were purchased from the Kunming Cell Bank of Type Culture Collection of the Chinese Academy of Sciences.
[0198] 8.4 Samples to be tested
[0199] Drug group:
[0200] 50 ppm reference peptide, 50 ppm peptide (1), 50 ppm peptide (3), 50 ppm peptide (5).
[0201] Control group:
[0202] PBS blank control.
[0203] 8.5 Experimental methods
[0204] Cryopreserved HaCaT cells were cultured and passaged at a ratio of 1:2 until about the fifth generation, and cells with better growth were selected as experimental subjects.
[0205] When the cells grew to about 80%, the UV radiation-stimulated inflammation model was established. The control group was added with PBS solution and supplemented with culture medium to 1000 μL without UV irradiation; the UV group and the drug-treated group were placed at 80 J / cm 3After irradiation, PBS solution and culture medium were added to the UV group to make up to 1000 μL, and the drug group was added with double dilution of active substance and culture medium to make up to 1000 μL. The control group, UV group, and drug group continued to be incubated at 37°C and 5% CO 2 Incubate in an incubator for 48 hours. After the incubation, centrifuge at 3000 rpm for 10 minutes, collect the cell supernatant to obtain the sample solution, and operate according to the instructions of the IL-6 and TNF-α kits.
[0206] 8.6 Results
[0207] Ultraviolet radiation can stimulate inflammatory responses in the skin, leading to increased secretion of TNF-α and IL-6. Therefore, inhibiting the secretion of inflammatory factors such as IL-6 and TNF-α can play an anti-inflammatory role.
[0208] The results of the effects of 50ppm of the peptide derivatives of the present invention on the expression of inflammatory factors such as IL-6 and TNF-α are shown in Figure 3 , Figure 4 . Figure 3 The results showed that compared with the control group, the IL-6 in the UV group increased significantly after UV irradiation. After administration, the reference peptide, peptide (1), peptide (3), and peptide (5) could significantly downregulate the expression of IL-6, and the differences between the peptide (1), peptide (3), and peptide (5) administration groups and the UV group were extremely significant, and they had higher anti-inflammatory activity than the reference peptide.
[0209] Figure 4 The results showed that compared with the control group, the TNF-α in the UV group increased significantly after UV irradiation. After administration, the reference peptide could inhibit the expression of TNF-α to a certain extent, but the inhibitory effect was not obvious; peptide (1), peptide (3), and peptide (5) could more significantly downregulate the expression of TNF-α and had higher anti-inflammatory activity than the reference peptide.
[0210] In summary, the new structural compounds peptide (1), peptide (3), and peptide (5) obtained by covalently linking the N-terminus of the reference peptide to NA, TXC, and KA can significantly downregulate the expression of IL-6 and TNF-α, and have a better effect than the reference peptide alone, and show unexpected anti-inflammatory activity on the basis of whitening effect. This shows that the peptide derivatives of the present invention have both whitening and anti-inflammatory activities, and can be used in the field of cosmetics or medicine for skin anti-inflammatory and whitening freckle removal, especially for improving post-inflammatory pigmentation.
[0211] Example 9 Preparation of toner containing peptide (1)
[0212]
[0213]
[0214] Dissolve allantoin and glycerin in water, heat to 85°C, and keep warm for 30 minutes; dissolve PEG-7 glyceryl cocoate and peptide (1) in water; mix and stir the above solutions after cooling to obtain a mixed solution; add propylene glycol, preservatives, and flavors to the above mixed solution in sequence, add water and stir to obtain a mixed solution.
[0215] Example 10 Preparation of cleansing gel containing peptide (3)
[0216]
[0217] Dissolve the peptide (3) in water and stir evenly to obtain a polypeptide solution; dissolve carbomer and EDTA in water, heat to 85°C, keep warm for 30 minutes, add triethanolamine after cooling, stir evenly to obtain a mixed solution; add the above mixed solution, polypeptide solution, preservative and flavor into water in turn and stir until completely swollen to obtain the product.
[0218] Example 11 Emulsion composition containing peptide (5)
[0219]
[0220]
[0221] Prepare 0.01g of peptide (5) into a 0.02mg / mL aqueous solution; heat cetearyl alcohol (and) cetearyl glucoside, jojoba oil, mineral oil, and isopropyl palmitate to 85°C and stir evenly to obtain phase A; dissolve glycerol, allantoin, polyacrylamide (and) C13-14 isoparaffin (and) laureth-7 in water and heat to 85°C to obtain phase B; quickly add phase A to phase B, homogenize at a constant temperature for 3-5 minutes, and cool; add a preservative when cooled to below 60°C, stir evenly, and add a polypeptide solution and flavor when cooled to below 45°C to obtain the product.
[0222] The above content is a further detailed description of the present invention in combination with specific preferred embodiments, but it does not mean that the specific implementation of the present invention is limited to these descriptions. For ordinary technicians in the field to which the present invention belongs, several simple deductions or substitutions can be made without departing from the concept of the present invention, which should be regarded as belonging to the protection scope of the present invention.
Claims
1. The following peptide derivatives (1) to peptide derivatives (4), or cosmetically acceptable salts thereof, or pharmaceutically acceptable salts thereof: (1) (2) (3) (4) 2. The peptide derivative according to claim 1, or a cosmetically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, characterized in that: The cosmetically acceptable salts or pharmaceutically acceptable salts include metal salts of the peptide derivatives, the metals including lithium, sodium, potassium, calcium, magnesium, manganese, copper, zinc or aluminum.
3. The peptide derivative according to claim 1, or a cosmetically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, characterized in that: The cosmetically acceptable salt or pharmaceutically acceptable salt includes a salt formed by the peptide derivative and an organic base, and the organic base includes ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, arginine, lysine, histidine or piperazine.
4. The peptide derivative according to claim 1, or a cosmetically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, characterized in that: The cosmetically acceptable salt or pharmaceutically acceptable salt includes a salt formed by the peptide derivative and an inorganic acid or an organic acid, wherein the organic acid includes acetic acid, citric acid, lactic acid, malonic acid, maleic acid, tartaric acid, fumaric acid, benzoic acid, aspartic acid, glutamic acid, succinic acid, oleic acid, trifluoroacetic acid, oxalic acid, pamoic acid or gluconic acid, and the inorganic acid includes hydrochloric acid, sulfuric acid, boric acid or carbonic acid.
5. A cosmetic or pharmaceutical composition, characterized in that: The composition comprises an effective amount of the peptide derivative according to any one of claims 1 to 4, or a cosmetically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, and at least one excipient and optionally a cosmetically or pharmaceutically acceptable adjuvant.
6. The cosmetic or pharmaceutical composition according to claim 5, characterized in that The adjuvant is selected from the group consisting of: collagen synthesis stimulators, agents that regulate PGC-1α synthesis, agents that regulate the activity of PPARγ, agents that increase or decrease the triglyceride content of adipocytes, agents that stimulate or delay adipocyte differentiation, lipolytic agents or agents that stimulate fat decomposition, lipolytic agents, lipogenic agents, inhibitors of acetylcholine receptor aggregation, agents that inhibit muscle contraction, anticholinergic agents, elastase inhibitors, matrix metalloproteinase inhibitors, melanin synthesis stimulators or inhibitors, whitening agents or depigmenting agents, pigmentation promoting agents, self-tanning agents, anti-aging agents, NO-synthase inhibitors, 5α-reductase inhibitors, inhibitors of lysyl hydroxylase and / or prolyl hydroxylase, antioxidants, free radical scavengers and / or anti-air pollution agents, active carbonyl Base substance scavengers, anti-glycation agents, antihistamines, antiviral agents, antiparasitic agents, emulsifiers, emollients, organic solvents, liquid propellants, moisture retaining substances, alpha hydroxy acids, beta hydroxy acids, moisturizers, epidermal hydrolases, vitamins, amino acids, pigments, dyes, biopolymers, gelling polymers, thickeners, surfactants, softeners, adhesives, preservatives, anti-wrinkle agents, agents capable of reducing or treating under-eye bags, keratolytic agents, antimicrobial agents, agents that stimulate the synthesis of dermal or epidermal macromolecules and / or are capable of inhibiting or preventing their degradation, agents that stimulate elastin synthesis, agents that stimulate decorin synthesis, agents that stimulate laminin synthesis, agents that stimulate defensin synthesis, agents that stimulate chaperone protein synthesis, agents that stimulate cA agents for stimulating MP synthesis, agents for stimulating hyaluronic acid synthesis, agents for stimulating fibronectin synthesis, agents for stimulating deacetylase synthesis, agents for stimulating the synthesis of lipids and stratum corneum components, ceramides, fatty acids, agents for inhibiting collagen degradation, agents for inhibiting elastin degradation, agents for inhibiting serine proteases, agents for stimulating fibroblast proliferation, agents for stimulating keratinocyte proliferation, agents for stimulating adipocyte proliferation, agents for stimulating melanocyte proliferation, agents for stimulating keratinocyte differentiation, agents for inhibiting acetylcholinesterase, skin relaxants, agents for stimulating glycosaminoglycan synthesis, anti-hyperkeratosis agents, comedolytic agents, anti-psoriatic agents, anti-eczema agents, DNA repair agents, DNA protective agents, stabilizers, antipruritic agents, for treating and / or caring for sensitive skin agents that stimulate healing, agents that assist healing, agents that stimulate re-epithelialization, agents that assist re-epithelialization, cytokines, sedatives, anti-inflammatory agents, anesthetics, agents that act on capillary circulation and / or microcirculation, agents that stimulate angiogenesis, agents that inhibit vascular permeability, agents that tone the veins, agents that act on cellular metabolism, agents for improving dermal-epidermal junctions, agents that induce hair growth, agents that inhibit or delay hair growth, fragrances, chelating agents, plant extracts, essential oils, marine extracts, agents obtained from biological fermentation processes, inorganic salts, cell extracts, sunscreens, and organic or inorganic photoprotective agents effective against ultraviolet A and / or B rays, or mixtures thereof.
7. The cosmetic or pharmaceutical composition according to claim 5 or 6, characterized in that: The formulation of the cosmetic or pharmaceutical composition is selected from the group consisting of: cream, oil, balm, foam, lotion, gel, liniment, serum, ointment, mousse, powder, stick, pen, spray, aerosol, capsule, tablet, granule, suspension, emulsion, elixir, polysaccharide film or jelly.
8. The cosmetic or pharmaceutical composition according to claim 7, characterized in that The capsules include soft capsules and hard capsules.
9. The cosmetic or pharmaceutical composition according to claim 7, characterized in that: The capsule is a gelatin capsule.
10. The cosmetic or pharmaceutical composition according to claim 7, characterized in that The tablets include: sugar-coated tablets.
11. A cosmetically or pharmaceutically acceptable delivery system or sustained-release system, characterized in that: A composition comprising an effective amount of a peptide derivative according to any one of claims 1 to 4, or a cosmetically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a cosmetic or pharmaceutical composition according to any one of claims 5 to 10; The cosmetically or pharmaceutically acceptable delivery system or sustained-release system is selected from: liposomes, oleosomes, ethosomes, millicapsules, microcapsules, nanocapsules, nanostructured lipid carriers, sponges, lipid vesicles, micelles, millispheres, microspheres, nanospheres, lipid spheres, microemulsions or nanoemulsions.
12. The cosmetically or pharmaceutically acceptable delivery system or sustained-release system according to claim 11, characterized in that: The cosmetically or pharmaceutically acceptable delivery system or sustained-release system is a liposome or a microemulsion.
13. The cosmetically or pharmaceutically acceptable delivery system or sustained-release system according to claim 11, characterized in that: The cosmetically or pharmaceutically acceptable delivery system or sustained-release system is a water-in-oil microemulsion having an internal structure of reverse micelles.
14. Use of the peptide derivative according to any one of claims 1 to 4, or a cosmetically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or the cosmetic or pharmaceutical composition according to any one of claims 5 to 10, or the cosmetically or pharmaceutically acceptable delivery system or sustained-release system according to any one of claims 11 to 13 in the preparation of a cosmetic composition or pharmaceutical composition for whitening.
15. Use of the peptide derivative according to any one of claims 1 to 4, or a cosmetically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or the cosmetic or pharmaceutical composition according to any one of claims 5 to 10, or the cosmetically or pharmaceutically acceptable delivery system or sustained-release system according to any one of claims 11 to 13 in the preparation of an anti-inflammatory cosmetic composition or pharmaceutical composition.
16. Use of the peptide derivative according to any one of claims 1 to 4, or a cosmetically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or the cosmetic or pharmaceutical composition according to any one of claims 5 to 10, or the cosmetically or pharmaceutically acceptable delivery system or sustained-release system according to any one of claims 11 to 13 in the preparation of a cosmetic composition or pharmaceutical composition for improving post-inflammatory pigmentation.
Citation Information
Patent Citations
Personal care and cosmetic composition containing tetrapeptides with the motifs gx1x2g, px1x2p, or px1x2k
CN101878019A
Tetrapeptides for brightening the skin
CN102573776A
Peptides useful in the treatment and / or care of the skin and / or mucous membranes and their use in cosmetic or pharmaceutical compositions
CN103314005A
Niacin-peptide having skin whitening activity and use for same
CN103957914A
Tranexamic acid-peptide having skin whitening activity and uses thereof
CN109311938A
